Neumora Therapeutics stock hits 52-week low at $1.65

In a challenging turn for Neumora Therapeutics, the biotech company’s stock has plummeted to a 52-week low, trading at $1.65. According to InvestingPro data, the stock’s RSI indicates oversold conditions, while analyst targets suggest significant upside potential, with price targets ranging from $4 to $30. This latest price level reflects a stark contrast to the company’s performance over the past year, with Neumora Therapeutics experiencing a precipitous 1-year change, down by an alarming 90.63%. Investors have been closely monitoring the stock, which has struggled to regain momentum amidst a broader market downturn affecting the biotech sector. The 52-week low serves as a critical juncture for Neumora Therapeutics as it seeks to navigate through the headwinds and reassure stakeholders of its long-term potential. Despite current challenges, the company maintains a strong liquidity position with a current ratio of 10.98 and more cash than debt on its balance sheet. Discover more insights about NMRA and 1,400+ other stocks with InvestingPro’s comprehensive research reports.

In other recent news, Neumora Therapeutics experienced a significant setback with its drug navacaprant failing to meet the primary endpoint in the phase 3 KOSTAL-1 trial for treating major depressive disorder (MDD). Despite this, BofA Securities maintained a Buy rating on the company’s stock, albeit with a reduced price target of $7.00, down from $22.00. Similarly, H.C. Wainwright reaffirmed its Buy rating with a steady price target of $30.00, while Mizuho (NYSE:MFG) Securities reiterated its Outperform rating with a price target of $20.00. However, RBC Capital Markets downgraded the stock to a Sector Perform rating and reduced the price target to $4.00.

Despite the disappointing trial results, analysts at BofA Securities, H.C. Wainwright, and Mizuho Securities remain optimistic about the potential outcomes from the remaining two trials, KOSTAL-2 and KOSTAL-3. They noted the possibility of positive outcomes, even after the unexpected failure of the KOSTAL-1 trial. On the other hand, RBC Capital analysts recommended a more cautious approach until Neumora can demonstrate recovery from this setback.

These recent developments indicate a mixed response from analysts following the failed trial, with some maintaining optimism for the future performance of Neumora Therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.